Patients receiving GLP-1 receptor agonists (primarily liraglutide and semaglutide) for an average of 21.7 weeks before bariatric surgery achieved 5.1% weight loss pre-operatively versus 2.4% in untreated patients, with 5.3kg greater fat mass reduction and preserved lean muscle mass. The enhanced weight loss persisted through one month post-surgery but equalized by six months.
This finding addresses a critical knowledge gap in optimizing bariatric surgery outcomes through pharmaceutical preparation. The preserved lean mass during GLP-1-induced weight loss contradicts concerns about muscle wasting with rapid pre-surgical weight reduction. For the growing population considering bariatric surgery, this suggests GLP-1 agonists could serve as valuable bridge therapy, potentially improving surgical safety through reduced operative risk associated with lower body weight. However, the temporary nature of the advantage—disappearing by six months—raises questions about long-term value beyond immediate perioperative benefits. The small sample size (86 patients) and retrospective design limit definitive conclusions, but the muscle-sparing profile of GLP-1 pre-treatment represents a meaningful clinical consideration for surgical candidates seeking to optimize their metabolic foundation before intervention.